Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6Gastrointestinal 6Breast 6Gynecologic 5Other hematologic neoplasm 3Tumor-Agnostic 2Thoracic 2Sarcoma 2Other solid neoplasm 1Myeloid 1Endocrine 1Dermatologic 1

Conditions

Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 25Magnetic Resonance Spectroscopy 13pembrolizumab 12pasireotide 12Sunitinib 11Octreotide 11lanreotide 10cabozantinib 10lenvatinib 8Sorafenib 8Cisplatin 8Temozolomide 7Etoposide 7Bevacizumab 7pazopanib 6Paclitaxel 6Nivolumab 6Doxorubicin 6Carboplatin 6Capecitabine 6vandetanib 5gallium Ga 68 dotatate 5Specimen Handling 5trametinib 4lutetium Lu 177 dotatate 4dabrafenib 4Mitotane 4Iodine-131 4telotristat ethyl 3surufatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Practice Guidelines as Topic × Endocrine × Clear all
NCT04032106 2025-03-14

HPV Vaccine Intervention for Young Sexual Minority Men

Ohio State University Comprehensive Cancer Center

Phase NA Completed
1,227 enrolled 8 charts
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡